Advertisement

Topics

Drug Eluting Pantera® LUX Catheter Registry

2014-07-23 21:09:55 | BioPortfolio

Summary

Evaluation of the safety and efficacy of the Pantera® Lux Paclitaxel releasing balloon for coronary arteries in daily clinical practice.

Description

All patients are treated with the Pantera® Lux Paclitaxel releasing balloon. The indication is in-stent restenosis in a coronary artery.

There will be follow-up assessments at 1, 6 and 12 months after coronary intervention. The clinical status will be evaluated at the different follow-up time points.

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Conditions

In-Stent Restenosis

Location

Herz-Kreislauf-Zentrum, Segeberger Kliniken GmbH
Bad Segeberg
Germany
23795

Status

Recruiting

Source

Biotronik AG

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-07-23T21:09:55-0400

Clinical Trials [747 Associated Clinical Trials listed on BioPortfolio]

Diffuse Type In-Stent Restenosis After Drug-Eluting Stent

To evaluate the best therapeutic option for the treatment of diffuse type post-drug-eluting stent restenosis.

The Valentines Trial

The primary objective of this multi-center, international, short term registry is to assess clinical success and efficacy of the paclitaxel eluting balloon treatment for in-stent restenosi...

Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis

The purpose of this study is to investigate the use of systemic intracoronary administration of albumin-bound paclitaxel, ABI-007, for the prevention and reduction of restenosis following ...

Clinical Evaluation of Patients With Everolimus-eluting Stent Xience V® Implanted in the Treatment of Restenosis in Non-coated Metallic Stent (BMS In-stent Restenosis) During a 2 Year Clinical Follow-up Period

Interventional, prospective, non-randomized, non-comparative, open and multicentric study of patients with everolimus-eluting stent " Xience V® " implanted in the treatment of restenosis ...

Focal In-Stent Restenosis After Drug-Eluting Stent

To evaluate the optimal management of focal in-stent restenosis after drug-eluting stent implantation with sirolimus-eluting implantation versus cutting balloon angioplasty

PubMed Articles [462 Associated PubMed Articles listed on BioPortfolio]

Therapeutic Options for In-Stent Restenosis.

In-stent restenosis (ISR) is a complex disease process that became apparent shortly after the introduction of stents into clinical practice. This review seeks to define in-stent restenosis (ISR) as we...

Incidence and Predictors of reCurrent Restenosis After Drug-coated Balloon Angioplasty for Restenosis of a drUg-eluting Stent: The ICARUS Cooperation.

The incidence and predictors of recurrent restenosis after drug-coated balloon (DCB) angioplasty for drug-eluting stent (DES) restenosis remain poorly studied. We sought to evaluate the incidence and ...

The SABRE Trial (Sirolimus Angioplasty Balloon for Coronary In-Stent Restenosis): Angiographic Results and 1-Year Clinical Outcomes.

The aim of this first-in-human study was to assess the safety and effectiveness of the Virtue sirolimus-eluting balloon in a cohort of patients with in-stent restenosis (ISR).

Impact of stent deformity induced by the kissing balloon technique for bifurcating lesions on in-stent restenosis after coronary intervention.

To investigate the impact of stent deformity induced by final kissing balloon technique (KBT) for coronary bifurcation lesions on in-stent restenosis (ISR).

Prognostic Value of Type D Personality for In-stent Restenosis in Coronary Artery Disease Patients Treated with Drug -Eluting Stent.

To evaluate the predictive value of Type D personality on in-stent restenosis (ISR) rates at 1- and 2-year post percutaneous coronary intervention (PCI) in patients with coronary artery disease (CAD).

Medical and Biotech [MESH] Definitions

Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.

The new and thickened layer of scar tissue that forms on a PROSTHESIS, or as a result of vessel injury especially following ANGIOPLASTY or stent placement.

Surgical construction of an artificial opening (stoma) for external fistulization of a duct or vessel by insertion of a tube with or without a supportive stent.

Postoperative hemorrhage from an endovascular AORTIC ANEURYSM repaired with endoluminal placement of stent grafts (BLOOD VESSEL PROSTHESIS IMPLANTATION). It is associated with pressurization, expansion, and eventual rupture of the aneurysm.

A type of surgical portasystemic shunt to reduce portal hypertension with associated complications of esophageal varices and ascites. It is performed percutaneously through the jugular vein and involves the creation of an intrahepatic shunt between the hepatic vein and portal vein. The channel is maintained by a metallic stent. The procedure can be performed in patients who have failed sclerotherapy and is an additional option to the surgical techniques of portocaval, mesocaval, and splenorenal shunts. It takes one to three hours to perform. (JAMA 1995;273(23):1824-30)

More From BioPortfolio on "Drug Eluting Pantera® LUX Catheter Registry"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Stent
A stent is a small mesh tube that's used to treat narrow or weak arteries. Arteries are blood vessels that carry blood away from your heart to other parts of your body.  A stent is placed in an artery as part of a procedure called angioplasty. &...


Searches Linking to this Trial